R&D Treating the chronic diseases GLP-1s miss, with Laurent Auda... Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
R&D Searching for new weight loss treatments Using IP intelligence to guide R&D activity can also help companies to develop treatments that are more effective, with fewer side effects.
R&D Big promises, hard work: What 2026 will demand from pharma Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.
R&D Sponsored Unlocking the future of obesity treatment Obesity is more than a number on the scale, it’s a complex, malignant disease linked to diabetes, cardiovascular conditions, and even certain cancers.
R&D GLP-1s in CKD: Evidence, market leadership, and key insights... At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
